Fairfield Bush & CO. cut its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 10.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 37,940 shares of the company’s stock after selling 4,300 shares during the period. Fairfield Bush & CO.’s holdings in Novo Nordisk A/S were worth $2,284,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Renaissance Technologies LLC boosted its position in Novo Nordisk A/S by 5.8% during the 4th quarter. Renaissance Technologies LLC now owns 26,217,026 shares of the company’s stock worth $1,517,441,000 after purchasing an additional 1,430,310 shares during the period. First Trust Advisors LP raised its stake in shares of Novo Nordisk A/S by 21,329.5% in the 4th quarter. First Trust Advisors LP now owns 835,749 shares of the company’s stock valued at $48,373,000 after purchasing an additional 831,849 shares in the last quarter. Loomis Sayles & Co. L P raised its stake in shares of Novo Nordisk A/S by 3.5% in the 4th quarter. Loomis Sayles & Co. L P now owns 21,760,471 shares of the company’s stock valued at $1,259,496,000 after purchasing an additional 730,735 shares in the last quarter. Capital International Investors raised its stake in Novo Nordisk A/S by 41.8% during the fourth quarter. Capital International Investors now owns 1,894,836 shares of the company’s stock worth $109,673,000 after acquiring an additional 558,446 shares during the period. Finally, Amundi Pioneer Asset Management Inc. grew its position in Novo Nordisk A/S by 38.4% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 1,630,489 shares of the company’s stock worth $94,374,000 after purchasing an additional 452,344 shares during the last quarter. 6.69% of the stock is owned by institutional investors.

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. restated an “overweight” rating on shares of Novo Nordisk A/S in a report on Wednesday, May 13th. UBS Group lowered shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Monday, May 11th. Morgan Stanley restated an “equal weight” rating on shares of Novo Nordisk A/S in a research report on Monday, May 18th. ValuEngine raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Tuesday, March 3rd. Finally, Societe Generale reaffirmed a “sell” rating on shares of Novo Nordisk A/S in a research note on Thursday, May 7th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company. Novo Nordisk A/S has a consensus rating of “Hold” and a consensus price target of $163.55.

Shares of Novo Nordisk A/S stock traded down $0.46 on Wednesday, hitting $64.69. The company had a trading volume of 65,224 shares, compared to its average volume of 1,357,244. The stock has a 50-day moving average of $63.66 and a 200-day moving average of $59.97. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market capitalization of $151.81 billion, a P/E ratio of 25.28, a P/E/G ratio of 2.38 and a beta of 0.46. Novo Nordisk A/S has a twelve month low of $47.24 and a twelve month high of $66.10.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.75 EPS for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.07. The business had revenue of $5 billion for the quarter, compared to analyst estimates of $4.70 billion. Novo Nordisk A/S had a net margin of 31.91% and a return on equity of 73.87%. Equities analysts predict that Novo Nordisk A/S will post 2.67 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Article: What are the risks of holding treasury bonds?

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.